Ramaswamy’s Enzyvant scores a double-barreled FDA commitment to help hustle a rare disease drug through its BLA
Love him or hate him — and there are plenty of people in both camps — Vivek Ramaswamy’s companies move fast.
Just a little more than three …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.